QSBS in Minnesota: H.F. 2438 Conformity, 9.85% Top Rate, and What Medical Alley Founders Need to Know

Minnesota's conformity to Section 1202: H.F. 2438 and the May 2026 update

Minnesota computes individual income tax starting from federal adjusted gross income, modified by Minnesota-specific additions and subtractions under Minn. Stat. § 290.01. Rather than using rolling conformity — where the state perpetually references the IRC as currently in force — Minnesota uses static conformity, adopting the IRC as of a specific fixed date. Before 2026, Minnesota's conformity date was May 1, 2023, meaning the state's tax code reflected the IRC as it existed on that date — predating the OBBBA's July 4, 2025 enactment by over two years.¹

In 2026, the Minnesota Legislature enacted H.F. 2438, the state's omnibus tax bill, which advanced Minnesota's IRC conformity date from May 1, 2023 to May 1, 2026. Because the One Big Beautiful Bill Act (OBBBA) was signed on July 4, 2025, Minnesota's updated conformity date now captures the OBBBA's §1202 changes — including the $15 million exclusion cap, the tiered 3/4/5-year exclusion schedule, and the raised $75 million gross assets threshold for stock issued after July 4, 2025.²

H.F. 2438 did include selective decouplings from certain OBBBA provisions. Minnesota did not adopt the OBBBA's exclusion for tip and overtime income, the car loan interest deduction, expanded 529 credential distributions, or the increased federal SALT cap. For pass-through entities, Minnesota decoupled from OBBBA transition rules for R&E expenditures and required an 80% addback. Critically, Minnesota did not decouple from the OBBBA's §1202 changes. The enhanced QSBS rules — $15M cap, tiered 3/4/5-year exclusions, $75M gross assets — apply at the Minnesota state level for qualifying stock issued after July 4, 2025.²

Additionally, H.F. 2438 decoupled Minnesota from the OBBBA's Qualified Opportunity Zone (QOZ) benefits for tax years beginning after December 31, 2026 — meaning any capital gain deferred or excluded under the QOZ program will be added back to Minnesota taxable income. This QOZ decoupling is analytically separate from the §1202 QSBS analysis; QSBS and QOZ are distinct tax incentives, and the QOZ decoupling does not affect §1202 treatment.

Dual-track regime for pre- and post-OBBBA stock

Like the federal rules, Minnesota's H.F. 2438 conformity applies different exclusion terms depending on when the stock was issued:

• Stock issued before July 4, 2025 (pre-OBBBA): 100% exclusion requires a 5-year hold. The exclusion cap is the greater of $10 million or 10× adjusted basis. The company's gross assets must have been below $50 million at issuance.
• Stock issued on or after July 4, 2025 (post-OBBBA): Tiered exclusion — 50% at 3 years, 75% at 4 years, 100% at 5 years. The exclusion cap is the greater of $15 million or 10× adjusted basis. The gross assets threshold at issuance rises to $75 million.

Minnesota's conformity applies both tracks identically at the state level. A Minnesota founder with pre-OBBBA stock still needs a 5-year hold for the full exclusion; a founder with post-OBBBA stock can access partial exclusions starting at year 3, with the same 28% rate trap on the non-excluded portion at the 3- and 4-year tiers applying federally.

For the full OBBBA §1202 breakdown and planning implications, see the OBBBA QSBS guide. For holding period clock rules — including how the clock starts for ISOs, RSAs, and SAFEs, and what mergers and 83(b) elections do — see the holding period guide.

The 9.85% rate and what Section 1202 saves Minnesota founders

Minnesota uses a four-bracket graduated income tax structure. For 2026, the top rate of 9.85% applies to taxable income above $193,240 for single filers and above $322,650 for married filing jointly. Minnesota provides no preferential rate for long-term capital gains — every dollar of capital gain is taxed as ordinary income at these same rates. A Minnesota founder in the top bracket who sells appreciated stock without §1202 protection faces 9.85% state income tax on the entire gain, in addition to the 20% federal capital gains rate and the 3.8% net investment income tax.³

The §1202 exclusion eliminates Minnesota income tax entirely on the excluded gain. The state tax savings from the exclusion scale directly with exit size up to the applicable cap:

• On a $10 million pre-OBBBA qualifying exit: Minnesota tax savings = $10M × 9.85% = $985,000
• On a $15 million post-OBBBA qualifying exit: Minnesota tax savings = $15M × 9.85% = $1,477,500

These amounts stack on top of the federal savings. Federal LTCG at 20% plus NIIT at 3.8% on $15 million amounts to approximately $3,570,000 in federal tax eliminated by the 100% exclusion at year 5. The combined federal-plus-Minnesota benefit on a $15M qualifying exit exceeds $5 million in total tax eliminated. Minnesota's 9.85% top rate is among the higher rates in conforming states — well above Colorado's 4.4%, Georgia's 4.99%, or Illinois's 4.95% — making the state-level QSBS benefit correspondingly larger in absolute terms.

There are no Minnesota local income taxes. Unlike New York City (which adds up to 3.876% on top of state tax) or Philadelphia (which adds a 3.75% city wage tax), Minneapolis and St. Paul do not impose an additional city-level income tax. A Minnesota founder's state-level analysis is limited to the Minnesota state rates above.

Minnesota QSBS worked examples

Medical Alley: the §1202(e)(3) excluded-industry analysis for Minnesota founders

Minnesota is home to one of the highest concentrations of medical device and life sciences companies in the world. The corridor stretching from the Twin Cities north through Rochester to Duluth — branded as "Medical Alley" by the Minnesota Medical Alley Association — encompasses over 1,000 medical technology companies and tens of thousands of employees. Major anchors include Medtronic (global HQ in Dublin, operational HQ in Fridley, MN), Boston Scientific's substantial Minnesota operations, Abbott's medical devices division (which includes the former St. Jude Medical, acquired in 2017), Cardiovascular Systems Inc., Surmodics, Natus Medical, and hundreds of device startups at earlier stages.⁴

IRC §1202(e)(3)(A) excludes businesses "in the field of health" from the qualified trade or business definition. Because this exclusion is defined by field rather than by company description, the analysis is fact-intensive and does not turn on how a company describes itself:

Medical device manufacturers: the product versus services distinction

The §1202(e)(3)(A) health exclusion targets the performance of professional health services — not all companies that interact with the healthcare industry. A company that designs, engineers, manufactures, and sells physical medical devices or diagnostic instruments is not, in that primary activity, performing a health service. Courts and IRS guidance have consistently focused on whether the company's principal asset is the reputation or skill of its licensed health professionals, or whether it is primarily a product-based manufacturing operation:

• Likely qualified: Medical device manufacturers whose revenue comes from selling physical products — implants, surgical instruments, diagnostic equipment, wearable monitors, vascular grafts — to hospitals, clinicians, and distributors without employing clinicians or billing for clinical encounters. Companies whose primary value-creating assets are manufacturing equipment, patents, and engineering expertise rather than licensed professional staff. Biomedical engineering software companies whose products are embedded in or interface with devices but do not themselves render clinical decisions. Companies holding 510(k) or PMA clearances that sell to healthcare providers without operating clinical sites.
• Likely excluded: Telehealth platforms that directly employ licensed clinicians and bill for clinical services. Multi-site clinic operators and practice management companies, even those using sophisticated technology platforms. Home health agencies and nursing staffing companies. Behavioral health and substance use disorder treatment companies that primarily provide therapy and psychiatric services, even if delivered via digital tools.
• Gray area: Remote patient monitoring companies that manage ongoing care pathways on behalf of health systems — particularly where company-employed nurses or clinicians review and act on data. AI-enabled diagnostic platforms where a company-employed physician makes or co-signs the diagnostic determination. Digital therapeutic companies with both an FDA-cleared software product and a clinical services component. Companies that derive significant revenue from professional services related to device integration, installation, or ongoing clinical training. These require a fact-specific §1202(e)(3)(A) analysis — the mix of revenue, the nature of the company's licensed staff, and the primary purpose of customer-facing workflows all matter.

Life sciences and drug discovery

Minnesota has a growing life sciences sector beyond medical devices — biotech and drug discovery companies in the Twin Cities and Rochester benefit from proximity to the University of Minnesota, the Mayo Clinic, and 3M's health sciences operations. Clinical-stage and pre-revenue drug discovery companies that are developing therapeutic candidates generally do not perform health services as their primary business and are not typically excluded under §1202(e)(3)(A). The health-field exclusion is aimed at clinical care delivery, not basic or applied research. However, contract research organizations (CROs) that derive most of their revenue from professional scientific services provided to pharma clients may face analysis under the §1202(e)(3)(A) consulting or reputation exclusions — particularly if the CRO's primary value asset is the reputation or specialized skills of its principal investigators rather than a proprietary product pipeline.

Financial services sector

The Minneapolis–St. Paul metro is a major financial services hub — home to US Bancorp, Ameriprise Financial, Allianz Life, and numerous insurance and fintech companies. These entities are themselves excluded under §1202(e)(3)(A) (financial services, brokerage) and §1202(e)(3)(B) (banking, insurance, financing, investing). For founders at financial technology companies serving this ecosystem, the same product-versus-services distinction applies: B2B software companies that sell workflow or compliance tools to financial institutions, without themselves holding client money, issuing credit, or acting as a financial principal, are generally not excluded. A licensed fintech that transmits funds, underwrites loans, or manages client assets as principal will face exclusion analysis. See the excluded industries guide for the full §1202(e)(3) analysis.

Software, agtech, and retail technology

Minnesota's broader technology sector — SaaS companies, agtech startups in the agricultural analytics and precision farming space, retail technology companies serving Target's vendor ecosystem — generally does not implicate the §1202(e)(3) excluded-industry rules. Pure software companies that sell products to enterprise buyers without performing professional services as their primary revenue source are paradigmatic qualifying businesses under §1202. The key risk in software is the consulting-revenue fraction: if a Minnesota software company derives the majority of its revenue from bespoke professional services engagements rather than a scalable product, the §1202(e)(3)(A) consulting exclusion may apply. Agtech companies whose product is analytics software, crop modeling platforms, or precision-agriculture hardware are not in an excluded field; companies that primarily provide agronomic consulting services under professional licenses are more exposed.

Minnesota versus peer startup states: QSBS comparison

Minnesota's position for founders who live and work in the state is clearly favorable: the §1202 exclusion applies in full at the state level, including the OBBBA's enhanced terms, and the 9.85% top rate means the Minnesota state-level saving ($985K–$1.48M on a $10M–$15M qualifying exit) is among the largest of any conforming state. The Medical Alley excluded-industry analysis is the primary qualification risk that distinguishes Minnesota from states like Illinois or Colorado — but for device companies whose primary business is manufacturing rather than health services delivery, the exclusion should be accessible with proper documentation and legal analysis.

Planning priorities for Minnesota founders

1. Resolve the §1202(e)(3) excluded-industry question if your company touches healthcare or financial services

Minnesota's H.F. 2438 conformity is irrelevant if the company's shares fail the qualified-trade-or-business test. Medical Alley's density means a higher fraction of Minnesota founders hold shares in companies that must navigate the §1202(e)(3)(A) health-field exclusion than founders in most other states. Get a written §1202(e)(3) legal opinion before planning around gifting, trust structures, or hold-period optimization. The opinion should address the company's specific revenue model, whether licensed health professionals are the company's principal asset, and how IRS guidance and case law apply to the company's primary business activity. See the excluded industries guide and the qualification requirements guide.

2. Verify all eight qualification tests now, not at exit

The §1202 exclusion depends on facts that existed at issuance — not at sale. The company's C corporation status, gross assets at issuance (below $50M pre-OBBBA or $75M post-OBBBA), the active-business test, the original-issuance requirement, and the eligible-shareholder test all must have been met at the time the stock was acquired. For Minnesota founders in device companies that originated as LLCs and converted to C corporations, the timing of the conversion affects the holding period clock and the qualification determination. See the Section 1202 checklist and the LLC and S-Corp guide.

3. Reach the 5-year mark for post-OBBBA stock before selling

For stock issued after July 4, 2025, the OBBBA's tiered exclusion schedule applies in Minnesota exactly as it does federally. At a 4-year hold, the non-excluded 25% is taxed at the federal 28% maximum rate plus Minnesota at 9.85% plus federal NIIT at 3.8%. On a $15M exit, the total tax difference between year 4 and year 5 exceeds $1.55 million — with over $368,000 in Minnesota income tax alone. If a transaction timeline permits any flexibility, reaching the 5-year mark should be a dominant constraint for post-OBBBA stock. See the holding period guide.

4. Plan gifting and trust strategies before any transaction is signed

Minnesota's §1202 conformity applies at the donee level under §1202(h)(2). A Minnesota-resident family member or irrevocable non-grantor trust that receives gifted QSBS shares has its own separate §1202 exclusion cap — up to $15M post-OBBBA — for the same shares. A Minnesota founder with a $45M expected qualifying QSBS gain who gifts shares to two Minnesota-resident family members before signing a definitive agreement can potentially triple the available exclusion. The gift must occur before any binding obligation to sell (the anticipatory assignment of income rule). See the gifting and stacking guide and the trusts guide for the §1202(h) donee rules and non-grantor trust mechanics.

5. Document issuance facts now, before a transaction process begins

Minnesota's conformity does not reduce the federal documentation requirement: at the time of sale you must prove that all qualification tests were met at issuance. For Medical Alley founders, this means documenting not just the stock issuance facts (83(b) election, subscription agreement, attestation letter, gross assets certificate) but also the §1202(e)(3) qualified-trade-or-business position — ideally through a legal opinion obtained before any transaction process begins. If the company is acquired or goes public, §1202(h)(4) holding-period carryover documentation must also be maintained continuously. See the documentation guide.

6. Consider the QOZ decoupling if you are also evaluating post-2026 QOZ investments

For Minnesota founders who are considering reinvesting post-exit capital into Qualified Opportunity Zone funds, H.F. 2438's QOZ decoupling — effective for tax years beginning after December 31, 2026 — means that any future QOZ capital gain deferral or exclusion at the federal level will not be honored at the Minnesota state level. The deferred gain will be added back to Minnesota taxable income in the year the federal deferral or exclusion would otherwise apply. This is analytically separate from the §1202 QSBS analysis, but Minnesota founders evaluating post-exit diversification strategies should factor this into the comparison of §1202 exclusion, §1045 rollover, QOZ investment, DAF, and other post-exit options. See the post-exit investing guide.

Talk to a QSBS advisor about your Minnesota situation

Minnesota's H.F. 2438 conformity makes the state-level §1202 analysis clean — but the §1202(e)(3) excluded-industry question for Medical Alley device and life sciences companies, the federal qualification tests, the OBBBA dual-track holding period rules, and the gifting and trust planning window before a transaction all require professional review. A fee-only financial advisor who specializes in QSBS and founder liquidity can confirm qualification, model the full federal-plus-Minnesota tax picture, and coordinate the pre-transaction planning window before the exclusion opportunity closes.

Fee-only focus - No obligation - Privacy-minded matching - Built for seven-figure planning decisions